F. Giles

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Andreas Hochhaus, Gianantonio Rosti, Nicholas C.P. Cross et al. · Leukemia · 2015 · 107 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +8

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

John F. Seymour, D. W. Kim, E Rubin et al. · Blood Cancer Journal · 2014 · 64 citations · Full text

Medicine, Hematology, Oncology +17

Molecular analysis of Philadelphia positive essential thrombocythemia.

Philippe Martiat, Norbert Ifrah, Feyruz V. Rassool et al. · PubMed · 1989 · 54 citations

Medicine, Hematology, Pathology +8

Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

Philipp D. le Coutre, F. Giles, Andreas Hochhaus et al. · Journal of Clinical Oncology · 2009 · 28 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies

Thomas Fischer, Akash Patnaik, Kapil N. Bhalla et al. · Journal of Clinical Oncology · 2005 · 24 citations

Medicine, Oncology, Pharmacology +13